nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Myelosuppression—Lomustine—brain cancer	0.0137	0.0772	CcSEcCtD
Ruxolitinib—Contusion—Lomustine—brain cancer	0.00734	0.0415	CcSEcCtD
Ruxolitinib—Myelosuppression—Hydroxyurea—brain cancer	0.00671	0.038	CcSEcCtD
Ruxolitinib—Haemorrhage intracranial—Temozolomide—brain cancer	0.006	0.0339	CcSEcCtD
Ruxolitinib—Myelosuppression—Carmustine—brain cancer	0.00543	0.0307	CcSEcCtD
Ruxolitinib—Myelosuppression—Temozolomide—brain cancer	0.00525	0.0297	CcSEcCtD
Ruxolitinib—Myelosuppression—Etoposide—brain cancer	0.0042	0.0237	CcSEcCtD
Ruxolitinib—Pancytopenia—Lomustine—brain cancer	0.00382	0.0216	CcSEcCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—brain cancer	0.0035	0.5	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—brain cancer	0.0035	0.5	CbGdCrCtD
Ruxolitinib—Herpes zoster—Temozolomide—brain cancer	0.00327	0.0185	CcSEcCtD
Ruxolitinib—Haemoglobin—Lomustine—brain cancer	0.00323	0.0183	CcSEcCtD
Ruxolitinib—Haemorrhage—Lomustine—brain cancer	0.00322	0.0182	CcSEcCtD
Ruxolitinib—Infection—Carboplatin—brain cancer	0.0026	0.0147	CcSEcCtD
Ruxolitinib—Pancytopenia—Procarbazine—brain cancer	0.00242	0.0137	CcSEcCtD
Ruxolitinib—Infection—Lomustine—brain cancer	0.00227	0.0128	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lomustine—brain cancer	0.00224	0.0127	CcSEcCtD
Ruxolitinib—Haematuria—Procarbazine—brain cancer	0.00217	0.0123	CcSEcCtD
Ruxolitinib—Epistaxis—Procarbazine—brain cancer	0.00215	0.0121	CcSEcCtD
Ruxolitinib—Body temperature increased—Carboplatin—brain cancer	0.00207	0.0117	CcSEcCtD
Ruxolitinib—Haemoglobin—Procarbazine—brain cancer	0.00205	0.0116	CcSEcCtD
Ruxolitinib—Haemorrhage—Procarbazine—brain cancer	0.00204	0.0115	CcSEcCtD
Ruxolitinib—Pancytopenia—Hydroxyurea—brain cancer	0.00188	0.0106	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.00185	0.0104	CcSEcCtD
Ruxolitinib—Neutropenia—Hydroxyurea—brain cancer	0.00185	0.0104	CcSEcCtD
Ruxolitinib—Body temperature increased—Lomustine—brain cancer	0.00181	0.0102	CcSEcCtD
Ruxolitinib—Weight increased—Hydroxyurea—brain cancer	0.0018	0.0102	CcSEcCtD
Ruxolitinib—Infestation—Hydroxyurea—brain cancer	0.00176	0.00996	CcSEcCtD
Ruxolitinib—Infestation NOS—Hydroxyurea—brain cancer	0.00176	0.00996	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00167	0.00942	CcSEcCtD
Ruxolitinib—Anaemia—Procarbazine—brain cancer	0.00164	0.00929	CcSEcCtD
Ruxolitinib—Haemoglobin—Hydroxyurea—brain cancer	0.00159	0.00898	CcSEcCtD
Ruxolitinib—Haemorrhage—Hydroxyurea—brain cancer	0.00158	0.00894	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.00157	0.0089	CcSEcCtD
Ruxolitinib—PRKCE—cerebellum—brain cancer	0.00157	0.00449	CbGeAlD
Ruxolitinib—DAPK3—telencephalon—brain cancer	0.00156	0.00446	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—brain cancer	0.00155	0.00443	CbGeAlD
Ruxolitinib—PLK1—central nervous system—brain cancer	0.00155	0.00441	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—brain cancer	0.00155	0.00441	CbGeAlD
Ruxolitinib—MAST1—central nervous system—brain cancer	0.00155	0.00441	CbGeAlD
Ruxolitinib—Pancytopenia—Carmustine—brain cancer	0.00152	0.00857	CcSEcCtD
Ruxolitinib—RPS6KA6—cerebellum—brain cancer	0.00151	0.00431	CbGeAlD
Ruxolitinib—MAST1—cerebellum—brain cancer	0.00151	0.00431	CbGeAlD
Ruxolitinib—ROCK1—telencephalon—brain cancer	0.0015	0.00428	CbGeAlD
Ruxolitinib—Neutropenia—Carmustine—brain cancer	0.00149	0.00844	CcSEcCtD
Ruxolitinib—CAMK1—spinal cord—brain cancer	0.00149	0.00425	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—brain cancer	0.00147	0.00419	CbGeAlD
Ruxolitinib—Pancytopenia—Temozolomide—brain cancer	0.00147	0.00828	CcSEcCtD
Ruxolitinib—DCLK3—central nervous system—brain cancer	0.00147	0.00418	CbGeAlD
Ruxolitinib—DYRK1A—telencephalon—brain cancer	0.00146	0.00418	CbGeAlD
Ruxolitinib—BMPR2—telencephalon—brain cancer	0.00146	0.00416	CbGeAlD
Ruxolitinib—LRRK2—brainstem—brain cancer	0.00146	0.00416	CbGeAlD
Ruxolitinib—JAK1—gonad—brain cancer	0.00145	0.00415	CbGeAlD
Ruxolitinib—PLK4—gonad—brain cancer	0.00144	0.00412	CbGeAlD
Ruxolitinib—Neutropenia—Temozolomide—brain cancer	0.00144	0.00816	CcSEcCtD
Ruxolitinib—Infection—Procarbazine—brain cancer	0.00144	0.00815	CcSEcCtD
Ruxolitinib—PLK3—endocrine gland—brain cancer	0.00143	0.00409	CbGeAlD
Ruxolitinib—Thrombocytopenia—Procarbazine—brain cancer	0.00142	0.00803	CcSEcCtD
Ruxolitinib—DCLK1—pituitary gland—brain cancer	0.00142	0.00405	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—brain cancer	0.00142	0.00405	CbGeAlD
Ruxolitinib—PLK3—head—brain cancer	0.00141	0.00404	CbGeAlD
Ruxolitinib—PHKG2—gonad—brain cancer	0.00141	0.00403	CbGeAlD
Ruxolitinib—Weight increased—Temozolomide—brain cancer	0.0014	0.00794	CcSEcCtD
Ruxolitinib—Weight decreased—Temozolomide—brain cancer	0.0014	0.00789	CcSEcCtD
Ruxolitinib—Urinary tract infection—Carmustine—brain cancer	0.00138	0.00782	CcSEcCtD
Ruxolitinib—CAMK1D—pituitary gland—brain cancer	0.00138	0.00395	CbGeAlD
Ruxolitinib—Infestation NOS—Temozolomide—brain cancer	0.00138	0.00778	CcSEcCtD
Ruxolitinib—Infestation—Temozolomide—brain cancer	0.00138	0.00778	CcSEcCtD
Ruxolitinib—JAK1—medulla oblongata—brain cancer	0.00137	0.00391	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—brain cancer	0.00137	0.00391	CbGeAlD
Ruxolitinib—PRKG2—brain—brain cancer	0.00137	0.00391	CbGeAlD
Ruxolitinib—LTK—head—brain cancer	0.00136	0.0039	CbGeAlD
Ruxolitinib—HIPK2—gonad—brain cancer	0.00136	0.00387	CbGeAlD
Ruxolitinib—CAMK1—endocrine gland—brain cancer	0.00134	0.00382	CbGeAlD
Ruxolitinib—Urinary tract infection—Temozolomide—brain cancer	0.00134	0.00756	CcSEcCtD
Ruxolitinib—CAMK1D—medulla oblongata—brain cancer	0.00134	0.00381	CbGeAlD
Ruxolitinib—STK16—pituitary gland—brain cancer	0.00133	0.0038	CbGeAlD
Ruxolitinib—PHKG2—medulla oblongata—brain cancer	0.00133	0.00379	CbGeAlD
Ruxolitinib—CAMK1—head—brain cancer	0.00132	0.00377	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—brain cancer	0.00131	0.00373	CbGeAlD
Ruxolitinib—GRK1—brain—brain cancer	0.0013	0.00373	CbGeAlD
Ruxolitinib—CAMK2G—telencephalon—brain cancer	0.0013	0.00372	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Temozolomide—brain cancer	0.0013	0.00736	CcSEcCtD
Ruxolitinib—MARK2—endocrine gland—brain cancer	0.0013	0.00371	CbGeAlD
Ruxolitinib—LRRK2—telencephalon—brain cancer	0.00129	0.00369	CbGeAlD
Ruxolitinib—CLK2—gonad—brain cancer	0.00129	0.00369	CbGeAlD
Ruxolitinib—PLK3—central nervous system—brain cancer	0.00129	0.00368	CbGeAlD
Ruxolitinib—Haemoglobin—Carmustine—brain cancer	0.00128	0.00726	CcSEcCtD
Ruxolitinib—MARK2—head—brain cancer	0.00128	0.00366	CbGeAlD
Ruxolitinib—Haemorrhage—Carmustine—brain cancer	0.00128	0.00723	CcSEcCtD
Ruxolitinib—PRKCE—brain—brain cancer	0.00128	0.00365	CbGeAlD
Ruxolitinib—Anaemia—Hydroxyurea—brain cancer	0.00127	0.00719	CcSEcCtD
Ruxolitinib—DAPK3—pituitary gland—brain cancer	0.00127	0.00363	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.00126	0.00712	CcSEcCtD
Ruxolitinib—CLK2—pituitary gland—brain cancer	0.00126	0.0036	CbGeAlD
Ruxolitinib—Fatigue—Procarbazine—brain cancer	0.00125	0.00707	CcSEcCtD
Ruxolitinib—ROCK1—gonad—brain cancer	0.00125	0.00357	CbGeAlD
Ruxolitinib—JAK1—midbrain—brain cancer	0.00125	0.00357	CbGeAlD
Ruxolitinib—DCLK1—midbrain—brain cancer	0.00125	0.00357	CbGeAlD
Ruxolitinib—Haemoglobin—Temozolomide—brain cancer	0.00124	0.00702	CcSEcCtD
Ruxolitinib—Haemorrhage—Temozolomide—brain cancer	0.00124	0.00698	CcSEcCtD
Ruxolitinib—DAPK3—medulla oblongata—brain cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—RPS6KA6—brain—brain cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—PLK1—brain—brain cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—MAST1—brain—brain cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—DYRK1A—gonad—brain cancer	0.00122	0.00349	CbGeAlD
Ruxolitinib—JAK1—spinal cord—brain cancer	0.00122	0.00348	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—brain cancer	0.00122	0.00348	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—brain cancer	0.00121	0.00345	CbGeAlD
Ruxolitinib—DAPK2—midbrain—brain cancer	0.00119	0.00341	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—brain cancer	0.00119	0.00339	CbGeAlD
Ruxolitinib—MAP3K2—telencephalon—brain cancer	0.00118	0.00338	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—brain cancer	0.00118	0.00337	CbGeAlD
Ruxolitinib—Pancytopenia—Etoposide—brain cancer	0.00117	0.00663	CcSEcCtD
Ruxolitinib—MAP3K7—telencephalon—brain cancer	0.00117	0.00335	CbGeAlD
Ruxolitinib—MARK2—central nervous system—brain cancer	0.00117	0.00334	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—brain cancer	0.00116	0.00332	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00116	0.00658	CcSEcCtD
Ruxolitinib—DCLK3—brain—brain cancer	0.00116	0.00332	CbGeAlD
Ruxolitinib—Neutropenia—Etoposide—brain cancer	0.00115	0.00653	CcSEcCtD
Ruxolitinib—TYK2—telencephalon—brain cancer	0.00115	0.00329	CbGeAlD
Ruxolitinib—Body temperature increased—Procarbazine—brain cancer	0.00115	0.00649	CcSEcCtD
Ruxolitinib—MARK2—cerebellum—brain cancer	0.00114	0.00327	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—brain cancer	0.00114	0.00327	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—brain cancer	0.00114	0.00325	CbGeAlD
Ruxolitinib—IRAK1—telencephalon—brain cancer	0.00114	0.00325	CbGeAlD
Ruxolitinib—MKNK2—telencephalon—brain cancer	0.00114	0.00325	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—brain cancer	0.00113	0.00324	CbGeAlD
Ruxolitinib—DAPK3—midbrain—brain cancer	0.00112	0.0032	CbGeAlD
Ruxolitinib—Infection—Hydroxyurea—brain cancer	0.00112	0.00631	CcSEcCtD
Ruxolitinib—Malnutrition—Carmustine—brain cancer	0.00111	0.00629	CcSEcCtD
Ruxolitinib—JAK3—endocrine gland—brain cancer	0.00111	0.00316	CbGeAlD
Ruxolitinib—Nervous system disorder—Hydroxyurea—brain cancer	0.0011	0.00623	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—brain cancer	0.0011	0.00622	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—brain cancer	0.0011	0.00622	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.0011	0.00622	CcSEcCtD
Ruxolitinib—JAK1—endocrine gland—brain cancer	0.0011	0.00314	CbGeAlD
Ruxolitinib—DCLK1—endocrine gland—brain cancer	0.0011	0.00314	CbGeAlD
Ruxolitinib—DAPK3—spinal cord—brain cancer	0.00109	0.00312	CbGeAlD
Ruxolitinib—PLK4—endocrine gland—brain cancer	0.00109	0.00312	CbGeAlD
Ruxolitinib—Skin disorder—Hydroxyurea—brain cancer	0.00109	0.00617	CcSEcCtD
Ruxolitinib—JAK3—head—brain cancer	0.00109	0.00312	CbGeAlD
Ruxolitinib—BMP2K—gonad—brain cancer	0.00109	0.00311	CbGeAlD
Ruxolitinib—DCLK1—head—brain cancer	0.00108	0.0031	CbGeAlD
Ruxolitinib—JAK1—head—brain cancer	0.00108	0.0031	CbGeAlD
Ruxolitinib—LRRK2—gonad—brain cancer	0.00108	0.00308	CbGeAlD
Ruxolitinib—Malnutrition—Temozolomide—brain cancer	0.00108	0.00608	CcSEcCtD
Ruxolitinib—CAMK1D—endocrine gland—brain cancer	0.00107	0.00306	CbGeAlD
Ruxolitinib—PHKG2—endocrine gland—brain cancer	0.00107	0.00304	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—brain cancer	0.00106	0.00303	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—brain cancer	0.00106	0.00303	CbGeAlD
Ruxolitinib—CAMK1D—head—brain cancer	0.00106	0.00302	CbGeAlD
Ruxolitinib—PHKG2—head—brain cancer	0.00105	0.003	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—brain cancer	0.00105	0.003	CbGeAlD
Ruxolitinib—JAK2—telencephalon—brain cancer	0.00105	0.00299	CbGeAlD
Ruxolitinib—BMPR2—midbrain—brain cancer	0.00105	0.00299	CbGeAlD
Ruxolitinib—Asthenia—Procarbazine—brain cancer	0.00104	0.00589	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Etoposide—brain cancer	0.00104	0.00589	CcSEcCtD
Ruxolitinib—TAOK3—brainstem—brain cancer	0.00104	0.00296	CbGeAlD
Ruxolitinib—STK16—endocrine gland—brain cancer	0.00103	0.00294	CbGeAlD
Ruxolitinib—Anaemia—Carmustine—brain cancer	0.00103	0.00581	CcSEcCtD
Ruxolitinib—Pruritus—Procarbazine—brain cancer	0.00103	0.0058	CcSEcCtD
Ruxolitinib—HIPK2—endocrine gland—brain cancer	0.00103	0.00293	CbGeAlD
Ruxolitinib—CAMK2G—medulla oblongata—brain cancer	0.00102	0.00292	CbGeAlD
Ruxolitinib—PLK3—brain—brain cancer	0.00102	0.00292	CbGeAlD
Ruxolitinib—STK16—head—brain cancer	0.00102	0.00291	CbGeAlD
Ruxolitinib—LRRK2—medulla oblongata—brain cancer	0.00101	0.0029	CbGeAlD
Ruxolitinib—HIPK2—head—brain cancer	0.00101	0.00289	CbGeAlD
Ruxolitinib—JAK3—central nervous system—brain cancer	0.000996	0.00284	CbGeAlD
Ruxolitinib—Anaemia—Temozolomide—brain cancer	0.000994	0.00562	CcSEcCtD
Ruxolitinib—MAP3K19—head—brain cancer	0.000992	0.00283	CbGeAlD
Ruxolitinib—JAK1—central nervous system—brain cancer	0.00099	0.00283	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—brain cancer	0.00099	0.00283	CbGeAlD
Ruxolitinib—LTK—brain—brain cancer	0.000989	0.00282	CbGeAlD
Ruxolitinib—MAP3K2—gonad—brain cancer	0.000988	0.00282	CbGeAlD
Ruxolitinib—DAPK3—endocrine gland—brain cancer	0.000985	0.00281	CbGeAlD
Ruxolitinib—CLK2—endocrine gland—brain cancer	0.000976	0.00279	CbGeAlD
Ruxolitinib—JAK3—cerebellum—brain cancer	0.000973	0.00278	CbGeAlD
Ruxolitinib—DAPK3—head—brain cancer	0.000972	0.00278	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00097	0.00548	CcSEcCtD
Ruxolitinib—Fatigue—Hydroxyurea—brain cancer	0.000968	0.00547	CcSEcCtD
Ruxolitinib—JAK1—cerebellum—brain cancer	0.000967	0.00276	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—brain cancer	0.000967	0.00276	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—brain cancer	0.000966	0.00276	CbGeAlD
Ruxolitinib—CLK2—head—brain cancer	0.000963	0.00275	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—brain cancer	0.00096	0.00274	CbGeAlD
Ruxolitinib—Dizziness—Procarbazine—brain cancer	0.00096	0.00543	CcSEcCtD
Ruxolitinib—CAMK1—brain—brain cancer	0.000958	0.00274	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—brain cancer	0.000955	0.00273	CbGeAlD
Ruxolitinib—MKNK2—gonad—brain cancer	0.000948	0.00271	CbGeAlD
Ruxolitinib—ROCK1—endocrine gland—brain cancer	0.000946	0.0027	CbGeAlD
Ruxolitinib—CAMK1D—cerebellum—brain cancer	0.000944	0.0027	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—brain cancer	0.000939	0.00268	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—brain cancer	0.000937	0.00268	CbGeAlD
Ruxolitinib—BMP2K—midbrain—brain cancer	0.000936	0.00267	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—brain cancer	0.000936	0.00267	CbGeAlD
Ruxolitinib—ROCK1—head—brain cancer	0.000934	0.00267	CbGeAlD
Ruxolitinib—MARK2—brain—brain cancer	0.00093	0.00266	CbGeAlD
Ruxolitinib—STK16—central nervous system—brain cancer	0.000929	0.00265	CbGeAlD
Ruxolitinib—LRRK2—midbrain—brain cancer	0.000928	0.00265	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—brain cancer	0.000925	0.00264	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—brain cancer	0.000924	0.00264	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—brain cancer	0.000923	0.00264	CbGeAlD
Ruxolitinib—DYRK1A—endocrine gland—brain cancer	0.000922	0.00263	CbGeAlD
Ruxolitinib—MAP3K7—medulla oblongata—brain cancer	0.000921	0.00263	CbGeAlD
Ruxolitinib—TAOK3—telencephalon—brain cancer	0.00092	0.00263	CbGeAlD
Ruxolitinib—BMPR2—endocrine gland—brain cancer	0.000919	0.00262	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—brain cancer	0.000913	0.00261	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—brain cancer	0.000913	0.00261	CbGeAlD
Ruxolitinib—DYRK1A—head—brain cancer	0.000911	0.0026	CbGeAlD
Ruxolitinib—Headache—Procarbazine—brain cancer	0.000909	0.00514	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000909	0.00514	CcSEcCtD
Ruxolitinib—STK16—cerebellum—brain cancer	0.000908	0.00259	CbGeAlD
Ruxolitinib—BMPR2—head—brain cancer	0.000907	0.00259	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—brain cancer	0.000905	0.00258	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—brain cancer	0.000905	0.00258	CbGeAlD
Ruxolitinib—TYK2—medulla oblongata—brain cancer	0.000905	0.00258	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—brain cancer	0.000903	0.00258	CbGeAlD
Ruxolitinib—RET—pituitary gland—brain cancer	0.000902	0.00258	CbGeAlD
Ruxolitinib—Infection—Carmustine—brain cancer	0.000902	0.0051	CcSEcCtD
Ruxolitinib—MKNK2—medulla oblongata—brain cancer	0.000893	0.00255	CbGeAlD
Ruxolitinib—Thrombocytopenia—Carmustine—brain cancer	0.000889	0.00503	CcSEcCtD
Ruxolitinib—Body temperature increased—Hydroxyurea—brain cancer	0.000888	0.00502	CcSEcCtD
Ruxolitinib—DAPK3—central nervous system—brain cancer	0.000888	0.00254	CbGeAlD
Ruxolitinib—CLK2—central nervous system—brain cancer	0.000879	0.00251	CbGeAlD
Ruxolitinib—JAK2—gonad—brain cancer	0.000874	0.0025	CbGeAlD
Ruxolitinib—Infection—Temozolomide—brain cancer	0.000872	0.00493	CcSEcCtD
Ruxolitinib—RET—medulla oblongata—brain cancer	0.000871	0.00249	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—brain cancer	0.000868	0.00248	CbGeAlD
Ruxolitinib—Nervous system disorder—Temozolomide—brain cancer	0.000861	0.00486	CcSEcCtD
Ruxolitinib—TAOK2—brain—brain cancer	0.00086	0.00246	CbGeAlD
Ruxolitinib—CLK2—cerebellum—brain cancer	0.000859	0.00245	CbGeAlD
Ruxolitinib—Thrombocytopenia—Temozolomide—brain cancer	0.000859	0.00486	CcSEcCtD
Ruxolitinib—JAK2—pituitary gland—brain cancer	0.000853	0.00244	CbGeAlD
Ruxolitinib—Skin disorder—Temozolomide—brain cancer	0.000852	0.00482	CcSEcCtD
Ruxolitinib—ROCK1—central nervous system—brain cancer	0.000852	0.00243	CbGeAlD
Ruxolitinib—MAP3K3—gonad—brain cancer	0.000843	0.00241	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—brain cancer	0.000842	0.0024	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—brain cancer	0.000831	0.00237	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—brain cancer	0.000828	0.00236	CbGeAlD
Ruxolitinib—TYK2—midbrain—brain cancer	0.000827	0.00236	CbGeAlD
Ruxolitinib—JAK2—medulla oblongata—brain cancer	0.000823	0.00235	CbGeAlD
Ruxolitinib—BMP2K—endocrine gland—brain cancer	0.000822	0.00235	CbGeAlD
Ruxolitinib—CAMK2G—endocrine gland—brain cancer	0.000822	0.00235	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—brain cancer	0.000822	0.00235	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—brain cancer	0.000821	0.00235	CbGeAlD
Ruxolitinib—MKNK2—midbrain—brain cancer	0.000816	0.00233	CbGeAlD
Ruxolitinib—IRAK1—midbrain—brain cancer	0.000816	0.00233	CbGeAlD
Ruxolitinib—LRRK2—endocrine gland—brain cancer	0.000815	0.00233	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—brain cancer	0.000812	0.00232	CbGeAlD
Ruxolitinib—BMP2K—head—brain cancer	0.000812	0.00232	CbGeAlD
Ruxolitinib—CAMK2G—head—brain cancer	0.000812	0.00232	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—brain cancer	0.000809	0.00231	CbGeAlD
Ruxolitinib—TYK2—spinal cord—brain cancer	0.000807	0.0023	CbGeAlD
Ruxolitinib—Asthenia—Hydroxyurea—brain cancer	0.000806	0.00456	CcSEcCtD
Ruxolitinib—LRRK2—head—brain cancer	0.000804	0.0023	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—brain cancer	0.000796	0.00227	CbGeAlD
Ruxolitinib—RET—midbrain—brain cancer	0.000796	0.00227	CbGeAlD
Ruxolitinib—Anaemia—Etoposide—brain cancer	0.000795	0.0045	CcSEcCtD
Ruxolitinib—MAP3K3—medulla oblongata—brain cancer	0.000793	0.00227	CbGeAlD
Ruxolitinib—JAK3—brain—brain cancer	0.000791	0.00226	CbGeAlD
Ruxolitinib—JAK1—brain—brain cancer	0.000786	0.00224	CbGeAlD
Ruxolitinib—DCLK1—brain—brain cancer	0.000786	0.00224	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000784	0.00443	CcSEcCtD
Ruxolitinib—PLK4—brain—brain cancer	0.000781	0.00223	CbGeAlD
Ruxolitinib—RET—spinal cord—brain cancer	0.000776	0.00222	CbGeAlD
Ruxolitinib—NUAK2—cerebellum—brain cancer	0.000773	0.00221	CbGeAlD
Ruxolitinib—CAMK1D—brain—brain cancer	0.000767	0.00219	CbGeAlD
Ruxolitinib—PHKG2—brain—brain cancer	0.000762	0.00218	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000758	0.00428	CcSEcCtD
Ruxolitinib—Fatigue—Temozolomide—brain cancer	0.000757	0.00428	CcSEcCtD
Ruxolitinib—DAPK2—brain—brain cancer	0.000749	0.00214	CbGeAlD
Ruxolitinib—TAOK3—pituitary gland—brain cancer	0.000749	0.00214	CbGeAlD
Ruxolitinib—MAP3K2—endocrine gland—brain cancer	0.000746	0.00213	CbGeAlD
Ruxolitinib—Dizziness—Hydroxyurea—brain cancer	0.000743	0.0042	CcSEcCtD
Ruxolitinib—BMP2K—central nervous system—brain cancer	0.000741	0.00212	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—brain cancer	0.000741	0.00212	CbGeAlD
Ruxolitinib—STK16—brain—brain cancer	0.000737	0.00211	CbGeAlD
Ruxolitinib—MAP3K2—head—brain cancer	0.000737	0.0021	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—brain cancer	0.000734	0.0021	CbGeAlD
Ruxolitinib—JAK2—spinal cord—brain cancer	0.000734	0.0021	CbGeAlD
Ruxolitinib—HIPK2—brain—brain cancer	0.000733	0.00209	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000727	0.00411	CcSEcCtD
Ruxolitinib—TYK2—endocrine gland—brain cancer	0.000726	0.00207	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—brain cancer	0.000725	0.00207	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—brain cancer	0.000724	0.00207	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—brain cancer	0.000724	0.00207	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—brain cancer	0.000723	0.00207	CbGeAlD
Ruxolitinib—MAP3K19—brain—brain cancer	0.000719	0.00205	CbGeAlD
Ruxolitinib—Body temperature increased—Carmustine—brain cancer	0.000718	0.00406	CcSEcCtD
Ruxolitinib—LRRK2—cerebellum—brain cancer	0.000718	0.00205	CbGeAlD
Ruxolitinib—TYK2—head—brain cancer	0.000717	0.00205	CbGeAlD
Ruxolitinib—MKNK2—endocrine gland—brain cancer	0.000717	0.00205	CbGeAlD
Ruxolitinib—MKNK2—head—brain cancer	0.000708	0.00202	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—brain cancer	0.000707	0.00202	CbGeAlD
Ruxolitinib—DAPK3—brain—brain cancer	0.000705	0.00201	CbGeAlD
Ruxolitinib—Headache—Hydroxyurea—brain cancer	0.000704	0.00398	CcSEcCtD
Ruxolitinib—RET—endocrine gland—brain cancer	0.000699	0.002	CbGeAlD
Ruxolitinib—CLK2—brain—brain cancer	0.000698	0.00199	CbGeAlD
Ruxolitinib—Infection—Etoposide—brain cancer	0.000698	0.00394	CcSEcCtD
Ruxolitinib—Body temperature increased—Temozolomide—brain cancer	0.000694	0.00392	CcSEcCtD
Ruxolitinib—RET—head—brain cancer	0.00069	0.00197	CbGeAlD
Ruxolitinib—Thrombocytopenia—Etoposide—brain cancer	0.000688	0.00389	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—brain cancer	0.000682	0.00386	CcSEcCtD
Ruxolitinib—ROCK1—brain—brain cancer	0.000677	0.00193	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—brain cancer	0.000673	0.00192	CbGeAlD
Ruxolitinib—TAOK3—midbrain—brain cancer	0.000661	0.00189	CbGeAlD
Ruxolitinib—JAK2—endocrine gland—brain cancer	0.000661	0.00189	CbGeAlD
Ruxolitinib—DYRK1A—brain—brain cancer	0.00066	0.00188	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—brain cancer	0.000657	0.00188	CbGeAlD
Ruxolitinib—BMPR2—brain—brain cancer	0.000657	0.00188	CbGeAlD
Ruxolitinib—TYK2—central nervous system—brain cancer	0.000654	0.00187	CbGeAlD
Ruxolitinib—JAK2—head—brain cancer	0.000652	0.00186	CbGeAlD
Ruxolitinib—Asthenia—Carmustine—brain cancer	0.000652	0.00368	CcSEcCtD
Ruxolitinib—MAP3K7—cerebellum—brain cancer	0.000651	0.00186	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—brain cancer	0.000646	0.00184	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—brain cancer	0.000645	0.00184	CbGeAlD
Ruxolitinib—TYK2—cerebellum—brain cancer	0.00064	0.00183	CbGeAlD
Ruxolitinib—MAP3K3—endocrine gland—brain cancer	0.000637	0.00182	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—brain cancer	0.000631	0.0018	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—brain cancer	0.000631	0.0018	CbGeAlD
Ruxolitinib—RET—central nervous system—brain cancer	0.00063	0.0018	CbGeAlD
Ruxolitinib—Asthenia—Temozolomide—brain cancer	0.00063	0.00356	CcSEcCtD
Ruxolitinib—MAP3K3—head—brain cancer	0.000629	0.0018	CbGeAlD
Ruxolitinib—NUAK2—brain—brain cancer	0.000628	0.00179	CbGeAlD
Ruxolitinib—Pruritus—Temozolomide—brain cancer	0.000621	0.00351	CcSEcCtD
Ruxolitinib—RET—cerebellum—brain cancer	0.000616	0.00176	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000606	0.00343	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—brain cancer	0.000605	0.00342	CcSEcCtD
Ruxolitinib—Dizziness—Carmustine—brain cancer	0.0006	0.00339	CcSEcCtD
Ruxolitinib—JAK2—central nervous system—brain cancer	0.000595	0.0017	CbGeAlD
Ruxolitinib—BMP2K—brain—brain cancer	0.000588	0.00168	CbGeAlD
Ruxolitinib—CAMK2G—brain—brain cancer	0.000588	0.00168	CbGeAlD
Ruxolitinib—LRRK2—brain—brain cancer	0.000583	0.00166	CbGeAlD
Ruxolitinib—JAK2—cerebellum—brain cancer	0.000582	0.00166	CbGeAlD
Ruxolitinib—TAOK3—endocrine gland—brain cancer	0.000581	0.00166	CbGeAlD
Ruxolitinib—Dizziness—Temozolomide—brain cancer	0.00058	0.00328	CcSEcCtD
Ruxolitinib—MAP3K3—central nervous system—brain cancer	0.000574	0.00164	CbGeAlD
Ruxolitinib—TAOK3—head—brain cancer	0.000573	0.00164	CbGeAlD
Ruxolitinib—Headache—Carmustine—brain cancer	0.000569	0.00322	CcSEcCtD
Ruxolitinib—MAP3K3—cerebellum—brain cancer	0.000561	0.0016	CbGeAlD
Ruxolitinib—Body temperature increased—Etoposide—brain cancer	0.000555	0.00314	CcSEcCtD
Ruxolitinib—Headache—Temozolomide—brain cancer	0.00055	0.00311	CcSEcCtD
Ruxolitinib—MAP3K2—brain—brain cancer	0.000534	0.00153	CbGeAlD
Ruxolitinib—MAP3K7—brain—brain cancer	0.000529	0.00151	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—brain cancer	0.000523	0.00149	CbGeAlD
Ruxolitinib—TYK2—brain—brain cancer	0.00052	0.00148	CbGeAlD
Ruxolitinib—MKNK2—brain—brain cancer	0.000513	0.00146	CbGeAlD
Ruxolitinib—IRAK1—brain—brain cancer	0.000513	0.00146	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—brain cancer	0.000511	0.00146	CbGeAlD
Ruxolitinib—Asthenia—Etoposide—brain cancer	0.000504	0.00285	CcSEcCtD
Ruxolitinib—RET—brain—brain cancer	0.0005	0.00143	CbGeAlD
Ruxolitinib—Pruritus—Etoposide—brain cancer	0.000497	0.00281	CcSEcCtD
Ruxolitinib—JAK2—brain—brain cancer	0.000473	0.00135	CbGeAlD
Ruxolitinib—Dizziness—Etoposide—brain cancer	0.000464	0.00262	CcSEcCtD
Ruxolitinib—MAP3K3—brain—brain cancer	0.000456	0.0013	CbGeAlD
Ruxolitinib—Headache—Etoposide—brain cancer	0.00044	0.00249	CcSEcCtD
Ruxolitinib—TAOK3—brain—brain cancer	0.000415	0.00119	CbGeAlD
Ruxolitinib—CYP3A4—endocrine gland—brain cancer	0.000176	0.000504	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—brain cancer	0.000159	0.000454	CbGeAlD
Ruxolitinib—JAK3—Signaling Pathways—IRS2—brain cancer	2.11e-05	4.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—RELA—brain cancer	2.11e-05	4.53e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—STAT3—brain cancer	2.11e-05	4.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—IL2—brain cancer	2.11e-05	4.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—ERBB2—brain cancer	2.1e-05	4.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CTNNB1—brain cancer	2.08e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRS2—brain cancer	2.08e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CTNNB1—brain cancer	2.07e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MYC—brain cancer	2.07e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—IL2—brain cancer	2.07e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PDGFRA—brain cancer	2.07e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—brain cancer	2.04e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—brain cancer	2.04e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PDGFRA—brain cancer	2.04e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL2—brain cancer	2.03e-05	4.36e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—brain cancer	2.03e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—STAT3—brain cancer	2.03e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—VAV1—brain cancer	2.02e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH2—brain cancer	2.02e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—STAT3—brain cancer	2.02e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—brain cancer	2.01e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS2—brain cancer	2.01e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SPP1—brain cancer	2.01e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CG—brain cancer	2.01e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SPP1—brain cancer	1.98e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CTNNB1—brain cancer	1.96e-05	4.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SHH—brain cancer	1.96e-05	4.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH2—brain cancer	1.96e-05	4.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—RELA—brain cancer	1.94e-05	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ERBB2—brain cancer	1.93e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VAV1—brain cancer	1.92e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—brain cancer	1.92e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS2—brain cancer	1.92e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL2—brain cancer	1.91e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH2—brain cancer	1.9e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TRPC6—brain cancer	1.89e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL2—brain cancer	1.88e-05	4.04e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MYC—brain cancer	1.87e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—STAT3—brain cancer	1.87e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VAV1—brain cancer	1.87e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—APC—brain cancer	1.87e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CG—brain cancer	1.87e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IL2—brain cancer	1.86e-05	4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—RELA—brain cancer	1.86e-05	4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTCH1—brain cancer	1.86e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMO—brain cancer	1.86e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—STAT3—brain cancer	1.86e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—ERBB2—brain cancer	1.85e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—brain cancer	1.84e-05	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—CTNNB1—brain cancer	1.84e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—brain cancer	1.83e-05	3.93e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS2—brain cancer	1.82e-05	3.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—STAT3—brain cancer	1.81e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VAV1—brain cancer	1.81e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—brain cancer	1.81e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PDGFRA—brain cancer	1.79e-05	3.85e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS2—brain cancer	1.79e-05	3.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ERBB2—brain cancer	1.78e-05	3.82e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2—brain cancer	1.75e-05	3.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—brain cancer	1.75e-05	3.75e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MYC—brain cancer	1.74e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HES1—brain cancer	1.74e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—RELA—brain cancer	1.73e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB2—brain cancer	1.72e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—STAT3—brain cancer	1.71e-05	3.67e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—brain cancer	1.7e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—brain cancer	1.7e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—brain cancer	1.7e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—brain cancer	1.69e-05	3.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—APC—brain cancer	1.69e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CTNNB1—brain cancer	1.69e-05	3.62e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—brain cancer	1.69e-05	3.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CG—brain cancer	1.67e-05	3.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PDGFRA—brain cancer	1.65e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HES1—brain cancer	1.65e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—brain cancer	1.65e-05	3.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—brain cancer	1.64e-05	3.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CTNNB1—brain cancer	1.62e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—brain cancer	1.62e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APC—brain cancer	1.61e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CG—brain cancer	1.61e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HES1—brain cancer	1.61e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—STAT3—brain cancer	1.6e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—brain cancer	1.58e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CG—brain cancer	1.58e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APC—brain cancer	1.58e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—brain cancer	1.58e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PDGFRA—brain cancer	1.57e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS2—brain cancer	1.57e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CTNNB1—brain cancer	1.56e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HES1—brain cancer	1.56e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—brain cancer	1.56e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—brain cancer	1.55e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—brain cancer	1.54e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SPP1—brain cancer	1.53e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PDGFRA—brain cancer	1.53e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CG—brain cancer	1.52e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—brain cancer	1.52e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CTNNB1—brain cancer	1.5e-05	3.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH2—brain cancer	1.48e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SPP1—brain cancer	1.48e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PDGFRA—brain cancer	1.48e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—RELA—brain cancer	1.48e-05	3.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—STAT3—brain cancer	1.47e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB2—brain cancer	1.47e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—brain cancer	1.46e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—RELA—brain cancer	1.46e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—brain cancer	1.45e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS2—brain cancer	1.45e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB2—brain cancer	1.45e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SPP1—brain cancer	1.44e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—brain cancer	1.44e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—RELA—brain cancer	1.43e-05	3.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB2—brain cancer	1.42e-05	3.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VAV1—brain cancer	1.41e-05	3.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—brain cancer	1.41e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—RELA—brain cancer	1.39e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS2—brain cancer	1.38e-05	2.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—brain cancer	1.38e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—brain cancer	1.36e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS2—brain cancer	1.34e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—brain cancer	1.34e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—brain cancer	1.33e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—brain cancer	1.32e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—brain cancer	1.31e-05	2.82e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—brain cancer	1.31e-05	2.82e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—brain cancer	1.31e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS2—brain cancer	1.3e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—brain cancer	1.29e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—brain cancer	1.28e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTNNB1—brain cancer	1.28e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APC—brain cancer	1.28e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—brain cancer	1.28e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—brain cancer	1.27e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—brain cancer	1.26e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RELA—brain cancer	1.25e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—brain cancer	1.25e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—brain cancer	1.25e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—brain cancer	1.25e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—brain cancer	1.23e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RELA—brain cancer	1.23e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—brain cancer	1.23e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CG—brain cancer	1.22e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APC—brain cancer	1.22e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—brain cancer	1.22e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HES1—brain cancer	1.22e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—brain cancer	1.21e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—brain cancer	1.2e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—brain cancer	1.19e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CG—brain cancer	1.19e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APC—brain cancer	1.19e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—brain cancer	1.18e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFRA—brain cancer	1.16e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—brain cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CG—brain cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APC—brain cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2C9—brain cancer	1.15e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—brain cancer	1.13e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPP1—brain cancer	1.12e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—brain cancer	1.12e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—brain cancer	1.12e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—brain cancer	1.11e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—brain cancer	1.11e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—brain cancer	1.1e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—brain cancer	1.09e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RELA—brain cancer	1.09e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—brain cancer	1.09e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—brain cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—brain cancer	1.08e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—brain cancer	1.08e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—brain cancer	1.07e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—brain cancer	1.07e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—brain cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—brain cancer	1.03e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—brain cancer	1.02e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—brain cancer	1.02e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—brain cancer	1e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—brain cancer	1e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—brain cancer	9.99e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—brain cancer	9.96e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—brain cancer	9.87e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—brain cancer	9.78e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BSG—brain cancer	9.74e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—brain cancer	9.6e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—brain cancer	9.57e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RELA—brain cancer	9.54e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—brain cancer	9.51e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—brain cancer	9.48e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—brain cancer	9.45e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—brain cancer	9.44e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—brain cancer	9.35e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—brain cancer	9.31e-06	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RELA—brain cancer	9.26e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—brain cancer	9.2e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—brain cancer	9.11e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—brain cancer	8.98e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—brain cancer	8.98e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RELA—brain cancer	8.98e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—brain cancer	8.93e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—brain cancer	8.84e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—brain cancer	8.72e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—brain cancer	8.69e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—brain cancer	8.64e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—brain cancer	8.59e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—brain cancer	8.5e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—brain cancer	8.43e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—brain cancer	8.38e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH1—brain cancer	8.37e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—brain cancer	8.34e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—brain cancer	8.3e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—brain cancer	8.23e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—brain cancer	8.18e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—brain cancer	8.13e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—brain cancer	8.09e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—brain cancer	8.05e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—brain cancer	7.89e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—brain cancer	7.81e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—brain cancer	7.6e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—brain cancer	7.48e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—brain cancer	7.3e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—brain cancer	7.26e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—brain cancer	7.23e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—brain cancer	7.14e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—brain cancer	7.09e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—brain cancer	7.06e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RELA—brain cancer	7.02e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—brain cancer	7.02e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—brain cancer	6.98e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—brain cancer	6.9e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—brain cancer	6.88e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—brain cancer	6.81e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—brain cancer	6.72e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—brain cancer	6.62e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—brain cancer	6.57e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—brain cancer	6.52e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—brain cancer	6.38e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—brain cancer	6.33e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—brain cancer	6.32e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—brain cancer	6.19e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—brain cancer	6.16e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—brain cancer	6.1e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—brain cancer	5.52e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—brain cancer	5.37e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—brain cancer	5.36e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—brain cancer	5.32e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—brain cancer	5.2e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—brain cancer	4.94e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—brain cancer	4.84e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—brain cancer	4.06e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—brain cancer	3.04e-06	6.52e-06	CbGpPWpGaD
